BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Banach M, Aronow WS, Serban MC, Rysz J, Voroneanu L, Covic A. Lipids, blood pressure and kidney update 2015. Lipids Health Dis 2015;14:167. [PMID: 26718096 DOI: 10.1186/s12944-015-0169-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 43] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Banach M, Nikolic D, Rizzo M, Toth PP. IMPROVE-IT: what have we learned? Curr Opin Cardiol 2016;31:426-33. [PMID: 27218683 DOI: 10.1097/HCO.0000000000000305] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Xuan C, Xu LQ, Tian QW, Li H, Wang Q, He GW, Lun LM. Dimethylarginine Dimethylaminohydrolase 2 (DDAH 2) Gene Polymorphism, Asymmetric Dimethylarginine (ADMA) Concentrations, and Risk of Coronary Artery Disease: A Case-Control Study. Sci Rep 2016;6:33934. [PMID: 27677852 DOI: 10.1038/srep33934] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
3 Huang H, Chen G, Liao D, Zhu Y, Xue X. Effects of Berries Consumption on Cardiovascular Risk Factors: A Meta-analysis with Trial Sequential Analysis of Randomized Controlled Trials. Sci Rep 2016;6:23625. [PMID: 27006201 DOI: 10.1038/srep23625] [Cited by in Crossref: 68] [Cited by in F6Publishing: 55] [Article Influence: 11.3] [Reference Citation Analysis]
4 Zhang Y, Zhang M, Yu X, Wei F, Chen C, Zhang K, Feng S, Wang Y, Li WD. Association of hypertension and hypertriglyceridemia on incident hyperuricemia: an 8-year prospective cohort study. J Transl Med 2020;18:409. [PMID: 33129322 DOI: 10.1186/s12967-020-02590-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Wang YX, Song L, Xing AJ, Gao M, Zhao HY, Li CH, Zhao HL, Chen SH, Lu CZ, Wu SL. Predictive Value of Cumulative Blood Pressure for All-Cause Mortality and Cardiovascular Events. Sci Rep 2017;7:41969. [PMID: 28167816 DOI: 10.1038/srep41969] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
6 Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Arch Med Sci 2017;13:965-1005. [PMID: 28883839 DOI: 10.5114/aoms.2017.69326] [Cited by in Crossref: 142] [Cited by in F6Publishing: 138] [Article Influence: 28.4] [Reference Citation Analysis]
7 Ganjali S, Dallinga-Thie GM, Simental-Mendía LE, Banach M, Pirro M, Sahebkar A. HDL functionality in type 1 diabetes. Atherosclerosis 2017;267:99-109. [PMID: 29102899 DOI: 10.1016/j.atherosclerosis.2017.10.018] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 5.8] [Reference Citation Analysis]
8 Banach M, Serban MC. Discussion around statin discontinuation in older adults and patients with wasting diseases. J Cachexia Sarcopenia Muscle 2016;7:396-9. [PMID: 27030814 DOI: 10.1002/jcsm.12109] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.7] [Reference Citation Analysis]
9 Sahebkar A, Serban MC, Gluba-Brzózka A, Mikhailidis DP, Cicero AF, Rysz J, Banach M. Lipid-modifying effects of nutraceuticals: An evidence-based approach. Nutrition 2016;32:1179-92. [PMID: 27324061 DOI: 10.1016/j.nut.2016.04.007] [Cited by in Crossref: 110] [Cited by in F6Publishing: 109] [Article Influence: 18.3] [Reference Citation Analysis]
10 Du Z, Bian W, Wu S, Gao B, Sun Y, Kang Z, Zhang X. Effects of blood pressure goals on cardiovascular outcomes in hypertensive patients. Arch Med Sci 2019;15:1381-7. [PMID: 31749865 DOI: 10.5114/aoms.2018.80013] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Xu L, Hao YT. Effect of handgrip on coronary artery disease and myocardial infarction: a Mendelian randomization study. Sci Rep 2017;7:954. [PMID: 28424468 DOI: 10.1038/s41598-017-01073-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
12 Feng X, Gao X, Yao Z, Xu Y. Low apoA-I is associated with insulin resistance in patients with impaired glucose tolerance: a cross-sectional study. Lipids Health Dis 2017;16:69. [PMID: 28372564 DOI: 10.1186/s12944-017-0446-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
13 González Sanchidrián S, Labrador Gómez PJ, Aguilar Aguilar JC, Davin Carrero E, Gallego Domínguez S, Gómez-Martino Arroyo JR. Evolocumab for the treatment of heterozygous familial hypercholesterolemia in end-stage chronic kidney disease and dialysis. Nefrologia (Engl Ed) 2019;39:218-20. [PMID: 30545713 DOI: 10.1016/j.nefro.2018.09.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Cicero AFG, Colletti A, Bajraktari G, Descamps O, Djuric DM, Ezhov M, Fras Z, Katsiki N, Langlois M, Latkovskis G, Panagiotakos DB, Paragh G, Mikhailidis DP, Mitchenko O, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Ray KK, Rizzo M, Sahebkar A, Serban MC, Sperling LS, Toth PP, Vinereanu D, Vrablík M, Wong ND, Banach M. Lipid-lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel. Nutr Rev 2017;75:731-67. [PMID: 28938795 DOI: 10.1093/nutrit/nux047] [Cited by in Crossref: 160] [Cited by in F6Publishing: 151] [Article Influence: 40.0] [Reference Citation Analysis]
15 Maierean S, Serban MC, Rizzo M, Lippi G, Sahebkar A, Banach M. The potential role of mitochondrial ATP synthase inhibitory factor 1 (IF1) in coronary heart disease: a literature review. Lipids Health Dis 2017;16:35. [PMID: 28173810 DOI: 10.1186/s12944-017-0430-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
16 Wang Y, Wang N, Lu Y, Yu Q, Zhou L, Xu Q. Detection of Apolipoprotein E Gene Polymorphism and Blood Lipid Level in Hemodialysis Patients. J Clin Med Res 2017;9:695-700. [PMID: 28725318 DOI: 10.14740/jocmr3046e] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
17 Banach M. Lipoprotein (a)-We Know So Much Yet Still Have Much to Learn …. J Am Heart Assoc 2016;5:e003597. [PMID: 27108250 DOI: 10.1161/JAHA.116.003597] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
18 Burlacu A, Siriopol D, Nistor I, Voroneanu L, Nedelciuc I, Statescu C, Covic A. Clinical SYNTAX Score - a good predictor for renal artery stenosis in acute myocardial infarction patients: analysis from the REN-ACS trial. Arch Med Sci 2017;13:837-44. [PMID: 28721152 DOI: 10.5114/aoms.2016.60374] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Kintoko K, Xu X, Lin X, Jiao Y, Wen Q, Chen Z, Wei J, Liang T, Huang R. Hypoglycaemic activity of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione in streptozotocin-induced diabetic mice through ameliorating metabolic function and regulating peroxisome proliferator-activated receptor γ. Arch Med Sci 2018;14:1163-72. [PMID: 30154901 DOI: 10.5114/aoms.2016.63285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
20 Bahrami A, Barreto GE, Lombardi G, Pirro M, Sahebkar A. Emerging roles for high‐density lipoproteins in neurodegenerative disorders. BioFactors 2019;45:725-39. [DOI: 10.1002/biof.1541] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
21 Sao R, Aronow WS. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis. Arch Med Sci 2018;14:1233-44. [PMID: 30393477 DOI: 10.5114/aoms.2017.68821] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
22 Kotani K, Serban MC, Penson P, Lippi G, Banach M. Evidence-based assessment of lipoprotein(a) as a risk biomarker for cardiovascular diseases - Some answers and still many questions. Crit Rev Clin Lab Sci 2016;53:370-8. [PMID: 27173621 DOI: 10.1080/10408363.2016.1188055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 30] [Article Influence: 4.5] [Reference Citation Analysis]
23 Rysz-Górzyńska M, Banach M. Subfractions of high-density lipoprotein (HDL) and dysfunctional HDL in chronic kidney disease patients. Arch Med Sci 2016;12:844-9. [PMID: 27478466 DOI: 10.5114/aoms.2016.60971] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
24 Maierean SM, Mikhailidis DP, Toth PP, Grzesiak M, Mazidi M, Maciejewski M, Banach M. The potential role of statins in preeclampsia and dyslipidemia during gestation: a narrative review. Expert Opinion on Investigational Drugs 2018;27:427-35. [DOI: 10.1080/13543784.2018.1465927] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
25 González Sanchidrián S, Labrador Gómez PJ, Aguilar Aguilar JC, Davin Carrero E, Gallego Domínguez S, Gómez-martino Arroyo JR. Evolocumab for the treatment of heterozygous familial hypercholesterolaemia in end-stage chronic kidney disease and dialysis. Nefrología (English Edition) 2019;39:218-20. [DOI: 10.1016/j.nefroe.2018.09.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Deng Y, Lin N, Wu L, Jia Q, Liu H. Expression of LOX-1 in human mesangial cells is increased by Ox-LDL and IL-1β treatment. Exp Ther Med 2017;14:3632-6. [PMID: 29042958 DOI: 10.3892/etm.2017.4950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
27 Liu H, Li Y, Lin N, Dong X, Li W, Deng Y, Ma L. Interleukin-1β Promotes Ox-LDL Uptake by Human Glomerular Mesangial Cells via LOX-1. Int J Med Sci 2020;17:1056-61. [PMID: 32410835 DOI: 10.7150/ijms.43981] [Reference Citation Analysis]
28 Rodríguez FOR, Santiago JC, Jiménez GM, Carreño Rodríguez YR, Meléndez AR, Medina Uicab CJ, Salas LN, Quiñones Gamero MA, Ramírez CDRG, Covarrubias LG, Mendoza MS, Hernández Rivera JCH, Sierra RP. Post-Transplant Cholesterol and Triglyceride Behavior: Effects of Sex, Age of the Recipient, and Type of Donor. Transplantation Proceedings 2020;52:1157-62. [DOI: 10.1016/j.transproceed.2020.01.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Lopatowska P, Mlodawska E, Tomaszuk-Kazberuk A, Banach M, Malyszko J. Adhering to the principles of clinical pharmacology - the correct fixed combinations of antihypertensive drugs. Expert Rev Clin Pharmacol 2018;11:165-70. [PMID: 29192802 DOI: 10.1080/17512433.2018.1412826] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
30 Muntean DM, Thompson PD, Catapano AL, Stasiolek M, Fabis J, Muntner P, Serban MC, Banach M. Statin-associated myopathy and the quest for biomarkers: can we effectively predict statin-associated muscle symptoms? Drug Discov Today 2017;22:85-96. [PMID: 27634340 DOI: 10.1016/j.drudis.2016.09.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 7.0] [Reference Citation Analysis]
31 Awad K, Penson P, Banach M. D-003 (Saccharum officinarum): The forgotten lipid-lowering agent. Pharmacol Res 2016;114:42-6. [PMID: 27751878 DOI: 10.1016/j.phrs.2016.10.008] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Banach M, Dinca M, Ursoniu S, Serban MC, Howard G, Mikhailidis DP, Nicholls S, Lip GYH, Glasser S, Martin SS, Muntner P, Rysz J, Toth PP, Sahebkar A; Lipid Blood Pressure Meta-analysis Collaboration Group. A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials investigating the effects of statin therapy on plasma lipid concentrations in HIV-infected patients. Pharmacol Res 2016;111:343-56. [PMID: 27350264 DOI: 10.1016/j.phrs.2016.06.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
33 Banach M, Jankowski P, Jóźwiak J, Cybulska B, Windak A, Guzik T, Mamcarz A, Broncel M, Tomasik T, Rysz J, Jankowska-Zduńczyk A, Hoffman P, Mastalerz-Migas A. PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Arch Med Sci 2017;13:1-45. [PMID: 28144253 DOI: 10.5114/aoms.2017.64712] [Cited by in Crossref: 37] [Cited by in F6Publishing: 46] [Article Influence: 6.2] [Reference Citation Analysis]
34 Banach M, Stulc T, Dent R, Toth PP. Statin non-adherence and residual cardiovascular risk: There is need for substantial improvement. Int J Cardiol 2016;225:184-96. [PMID: 27728862 DOI: 10.1016/j.ijcard.2016.09.075] [Cited by in Crossref: 82] [Cited by in F6Publishing: 88] [Article Influence: 13.7] [Reference Citation Analysis]
35 Rochlani Y, Khan MH, Banach M, Aronow WS. Are two drugs better than one? A review of combination therapies for hypertension. Expert Opinion on Pharmacotherapy 2017;18:377-86. [DOI: 10.1080/14656566.2017.1288719] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
36 Acuña‐aravena M, Cohen DE. Lipoprotein Metabolism and Cholesterol Balance. In: Arias IM, Alter HJ, Boyer JL, Cohen DE, Shafritz DA, Thorgeirsson SS, Wolkoff AW, editors. The Liver. Wiley; 2020. pp. 255-67. [DOI: 10.1002/9781119436812.ch22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Ganjali S, Momtazi AA, Banach M, Kovanen PT, Stein EA, Sahebkar A. HDL abnormalities in familial hypercholesterolemia: Focus on biological functions. Progress in Lipid Research 2017;67:16-26. [DOI: 10.1016/j.plipres.2017.05.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
38 Banach M, Rizzo M, Nikolic D, Howard G, Howard V, Mikhailidis D. Intensive LDL-cholesterol lowering therapy and neurocognitive function. Pharmacology & Therapeutics 2017;170:181-91. [DOI: 10.1016/j.pharmthera.2016.11.001] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
39 Penson P, Mcgowan M, Banach M. Evaluating bempedoic acid for the treatment of hyperlipidaemia. Expert Opinion on Investigational Drugs 2016;26:251-9. [DOI: 10.1080/13543784.2017.1280458] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 6.2] [Reference Citation Analysis]
40 Awad K, Mikhailidis DP, Toth PP, Jones SR, Moriarty P, Lip GYH, Muntner P, Catapano AL, Pencina MJ, Rosenson RS, Rysz J, Banach M; on behalf of the Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Efficacy and Safety of Alternate-Day Versus Daily Dosing of Statins: a Systematic Review and Meta-Analysis. Cardiovasc Drugs Ther 2017;31:419-31. [DOI: 10.1007/s10557-017-6743-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
41 Maierean SM, Serban M, Sahebkar A, Ursoniu S, Serban A, Penson P, Banach M. The effects of cinnamon supplementation on blood lipid concentrations: A systematic review and meta-analysis. Journal of Clinical Lipidology 2017;11:1393-406. [DOI: 10.1016/j.jacl.2017.08.004] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 6.2] [Reference Citation Analysis]
42 Gluba-Brzozka A, Franczyk B, Toth PP, Rysz J, Banach M. Molecular mechanisms of statin intolerance. Arch Med Sci 2016;12:645-58. [PMID: 27279860 DOI: 10.5114/aoms.2016.59938] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 5.0] [Reference Citation Analysis]
43 Muralikumar S, Vetrivel U, Narayanasamy A, N Das U. Probing the intermolecular interactions of PPARγ-LBD with polyunsaturated fatty acids and their anti-inflammatory metabolites to infer most potential binding moieties. Lipids Health Dis 2017;16:17. [PMID: 28109294 DOI: 10.1186/s12944-016-0404-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
44 Pirro M, Mannarino MR, Ministrini S, Fallarino F, Lupattelli G, Bianconi V, Bagaglia F, Mannarino E. Effects of a nutraceutical combination on lipids, inflammation and endothelial integrity in patients with subclinical inflammation: a randomized clinical trial. Sci Rep 2016;6:23587. [PMID: 27004462 DOI: 10.1038/srep23587] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
45 Rysz J, Gluba-brzózka A, Franczyk B, Banach M, Bartnicki P. Combination drug versus monotherapy for the treatment of autosomal dominant polycystic kidney disease. Expert Opinion on Pharmacotherapy 2016;17:2049-56. [DOI: 10.1080/14656566.2016.1232394] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]